{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:25:59Z","timestamp":1793989559717,"version":"4.8.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002471","name":"Dongguk University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002471","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104843","type":"journal-article","created":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:51:03Z","timestamp":1793119863000},"page":"104843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target\u2013modality\u2013formulation matching explains"],"prefix":"10.1016","volume":"31","author":[{"given":"Yohan","family":"Seo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5152-8057","authenticated-orcid":false,"given":"Joohan","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104843_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.drudis.2026.104843_b0010","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104843_b0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104843_b0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.drudis.2026.104843_b0025","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2026.104843_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.drudis.2026.104843_b0035","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0040","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.125.074545","article-title":"Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial","volume":"151","author":"Marx","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2026.104843_b0045","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s40265-026-02363-5","article-title":"Orforglipron: first approval","volume":"86","author":"Shirley","year":"2026","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104843_b0050","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/S0140-6736(26)00967-0","article-title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","volume":"407","author":"Bajaj","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104843_b0055","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0060","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide\u2013semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0065","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1038\/s41591-026-04476-6","article-title":"Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"32","author":"Rosenstock","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104843_b0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-026-04651-9","article-title":"Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial","author":"Yu","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104843_b0075","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/S0140-6736(26)00802-0","article-title":"Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial","volume":"407","author":"Aroda","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104843_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(26)00213-5","article-title":"Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial","author":"Garvey","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.drudis.2026.104843_b0085","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(26)01247-X","article-title":"Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial","volume":"408","author":"Mora","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104843_b0090","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1007\/s00125-025-06499-z","article-title":"The role of the beta cell in type 2 diabetes: new findings from the last 5 years","volume":"68","author":"Yau","year":"2025","journal-title":"Diabetologia"},{"key":"10.1016\/j.drudis.2026.104843_b0095","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","volume":"407","author":"Nauck","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104843_b0100","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.2147\/DDDT.S506957","article-title":"A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist","volume":"19","author":"Min","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.drudis.2026.104843_b0105","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.drudis.2026.104843_b0110","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.drudis.2026.104843_b0115","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2026.104843_b0120","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2026.104843_b0125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104843_b0135","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.tem.2013.03.003","article-title":"The fatty acid receptor FFA1\/GPR40 a decade later: how much do we know?","volume":"24","author":"Mancini","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.drudis.2026.104843_b0140","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature10798","article-title":"Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human","volume":"483","author":"Ichimura","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104843_b0145","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1021\/acs.chemrev.6b00056","article-title":"Complex pharmacology of free fatty acid receptors","volume":"117","author":"Milligan","year":"2017","journal-title":"Chem Rev"},{"key":"10.1016\/j.drudis.2026.104843_b0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.drudis.2026.104843_b0160","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104843_b0165","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.drudis.2026.104843_b0170","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S2213-8587(19)30087-7","article-title":"Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data","volume":"7","author":"Dennis","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.drudis.2026.104843_b0175","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1038\/s41591-023-02502-5","article-title":"Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine","volume":"29","author":"Tobias","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104843_b0180","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104843_b0185","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","article-title":"A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes","volume":"23","author":"Aroda","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.drudis.2026.104843_b0190","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/pharmaceutics11020078","article-title":"Intestinal permeation enhancers for oral delivery of macromolecules: a comparison between salcaprozate sodium (SNAC) and sodium caprate (C10)","volume":"11","author":"Twarog","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104843_b0195","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0200","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0205","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104843_b0210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"10.1016\/j.drudis.2026.104843_b0215","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0220","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0225","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2026.104843_b0230","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat3392","article-title":"Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models","volume":"10","author":"Killion","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2026.104843_b0235","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1038\/s41467-020-18751-8","article-title":"Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism","volume":"11","author":"Killion","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104843_b0240","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104843_b0245","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-monthly maridebart cafraglutide for the treatment of obesity \u2013 a phase 2 trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0250","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/dom.14712","article-title":"Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease","volume":"24","author":"Parker","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.drudis.2026.104843_b0255","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.drudis.2026.104843_b0260","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1056\/NEJMoa2600751","article-title":"Survodutide once weekly for the treatment of adults with obesity","volume":"395","author":"le Roux","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(26)01861-1","article-title":"Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial","author":"Bellido","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104843_b0270","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41467-018-03941-2","article-title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","volume":"9","author":"Jones","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104843_b0275","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.drudis.2026.104843_b0280","doi-asserted-by":"crossref","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist","volume":"117","author":"Kawai","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2026.104843_b0285","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR Review 25","volume":"175","author":"Hay","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104843_b0290","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-8587(26)00125-7","article-title":"Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study","volume":"14","author":"Buse","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.drudis.2026.104843_b0295","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/S0140-6736(25)02155-5","article-title":"Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial","volume":"406","author":"Billings","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104843_b0300","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1152\/physrev.00041.2018","article-title":"Free fatty acid receptors in health and disease","volume":"100","author":"Kimura","year":"2020","journal-title":"Physiol Rev"},{"key":"10.1016\/j.drudis.2026.104843_b0305","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40264-018-0642-6","article-title":"Liver safety of fasiglifam (TAK-875) in patients with type 2 diabetes: review of the global clinical trial experience","volume":"41","author":"Marcinak","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.drudis.2026.104843_b0310","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1124\/dmd.115.064121","article-title":"Fasiglifam (TAK-875) inhibits hepatobiliary transporters: a possible factor contributing to fasiglifam-induced liver injury","volume":"43","author":"Li","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.drudis.2026.104843_b0315","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4093\/dmj.2025.0528","article-title":"Efficacy and safety of HD-6277, a novel G protein-coupled receptor 40 agonist, in individuals with type 2 diabetes mellitus: a double-blind, randomized, placebo-controlled, parallel-group, multicenter phase 2 clinical trial","volume":"50","author":"Lee","year":"2026","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.drudis.2026.104843_b0320","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/13543784.2024.2321271","article-title":"GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates","volume":"33","author":"Hryciw","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.drudis.2026.104843_b0325","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.str.2026.05.007","article-title":"An extracellular allosteric gate modulates the ligand efficacy of GPR119","volume":"34","author":"Zhang","year":"2026","journal-title":"Structure"},{"key":"10.1016\/j.drudis.2026.104843_b0330","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.cell.2010.07.041","article-title":"GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects","volume":"142","author":"Oh","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104843_b0335","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104843_b0340","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0345","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes \u2013 5-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0350","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","article-title":"Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial","volume":"391","author":"Lean","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104843_b0355","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1152\/physrev.00008.2017","article-title":"Pancreatic \u03b2-cell electrical activity and insulin secretion: of mice and men","volume":"98","author":"Rorsman","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1016\/j.drudis.2026.104843_b0360","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev-physiol-030212-183754","article-title":"Regulation of insulin secretion in human pancreatic islets","volume":"75","author":"Rorsman","year":"2013","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.drudis.2026.104843_b0365","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jpain.2016.09.008","article-title":"Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study","volume":"18","author":"Simpson","year":"2017","journal-title":"J Pain"},{"key":"10.1016\/j.drudis.2026.104843_b0370","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2337\/dc16-2042","article-title":"Diabetic neuropathy: a position statement by the American Diabetes Association","volume":"40","author":"Pop-Busui","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.drudis.2026.104843_b0375","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1210\/jc.2011-3253","article-title":"Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: t-emerge 3 trial","volume":"97","author":"Henry","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.drudis.2026.104843_b0380","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2020.05.007","article-title":"Systemic delivery of peptides by the oral route: formulation and medicinal chemistry approaches","volume":"157","author":"Brayden","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.drudis.2026.104843_b0385","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2026.104843_b0390","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes","volume":"393","author":"Rosenstock","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0395","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s13300-024-01554-1","article-title":"Effect of food consumption on the pharmacokinetics, safety, and tolerability of once-daily orally administered orforglipron (LY3502970), a non-peptide GLP-1 receptor agonist","volume":"15","author":"Ma","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.drudis.2026.104843_b0400","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(26)00202-3","article-title":"Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial","volume":"407","author":"Rosenstock","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104843_b0405","unstructured":"FOUNDAYO (orforglipron) tablets, for oral use: highlights of prescribing information. US Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/220934Orig1s000lbl.pdf. Accessed October 1, 2026."},{"key":"10.1016\/j.drudis.2026.104843_b0410","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/cpt.70377","article-title":"Clinical characterization of enzyme and transporter precipitants to evaluate drug-drug interactions for orforglipron, a small molecule glucagon-like peptide-1 receptor agonist","volume":"120","author":"Morse","year":"2026","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104843_b0415","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1111\/dom.16534","article-title":"Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: a randomized, placebo-controlled, dose-ranging phase 2b study","volume":"27","author":"Buckeridge","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.drudis.2026.104843_b0420","unstructured":"Pfizer Inc. Pfizer provides update on oral GLP-1 receptor agonist danuglipron. Pfizer Inc Website. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-provides-update-oral-glp-1-receptor-agonist. Published April 14, 2025. Accessed October 1, 2026."},{"key":"10.1016\/j.drudis.2026.104843_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2026.100346","article-title":"Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids-application to recent real-world cases","volume":"54","author":"Li","year":"2026","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.drudis.2026.104843_b0430","doi-asserted-by":"crossref","first-page":"8347","DOI":"10.1111\/dom.71032","article-title":"Hepatic safety of orforglipron in adults with obesity or overweight and\/or type 2 diabetes: a pooled analysis of the orforglipron phase 3 clinical trials","volume":"28","author":"Wharton","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.drudis.2026.104843_b0435","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","article-title":"Advances in oral peptide therapeutics","volume":"19","author":"Drucker","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104843_b0440","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.drudis.2026.104843_b0445","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s11095-022-03288-w","article-title":"Review: role of model-informed drug development approaches in the lifecycle of drug development and regulatory decision-making","volume":"39","author":"Madabushi","year":"2022","journal-title":"Pharm Res"},{"key":"10.1016\/j.drudis.2026.104843_b0450","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1053\/j.gastro.2025.06.003","article-title":"Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis","volume":"169","author":"Chiang","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2026.104843_b0455","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.drudis.2026.104843_b0460","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0465","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0470","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s13300-021-01053-7","article-title":"Semaglutide once-weekly persistence and adherence versus other GLP-1 RAs in patients with type 2 diabetes in a US real-world setting","volume":"12","author":"Uzoigwe","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.drudis.2026.104843_b0475","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.2337\/dc16-1925","article-title":"Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis","volume":"40","author":"Khunti","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.drudis.2026.104843_b0480","unstructured":"ClinicalTrials.gov. US National Library of Medicine. https:\/\/clinicaltrials.gov. Accessed October 1, 2026."},{"key":"10.1016\/j.drudis.2026.104843_b0485","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/dom.12958","article-title":"Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes","volume":"19","author":"Guzman","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.drudis.2026.104843_b0490","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104843_b0495","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104843_b0500","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(26)01248-1","article-title":"Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial","volume":"408","author":"Mora","year":"2026","journal-title":"Lancet"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:49:18Z","timestamp":1793987358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002485"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104843","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target\u2013modality\u2013formulation matching explains","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104843"}}